DGAP-News: SYGNIS Pharma AG: Shareholders support Management proposals at
(firmenpresse) - DGAP-News: SYGNIS Pharma AG / Key word(s): AGM/EGM
SYGNIS Pharma AG: Shareholders support Management proposals at
30.08.2013 / 10:58
---------------------------------------------------------------------
Press Release
Shareholders support Management proposals at
SYGNIS Pharma's AGM with overwhelming majority
Madrid/Heidelberg, 30 August 2013 - At the Annual General Meeting (AGM) of
SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held
on 28 August 2013 shareholders representing about 94 percent of the capital
approved all proposals of the Management with an overwhelming majority.
Main decisions were related to the discharge of the members of the
Supervisory and the Management Board for the past Fiscal Year, the election
of new members of the Supervisory Board, the change of the trade name of
the Company (new trade name will be: SYGNIS AG), as well as the creation of
new authorised capital.
Dr. Wolf-Dieter Starp and Mr. Gonzalo Rodriguez-Fraile Díaz have left the
Supervisory Board. Dr. Cristina Garmendia Mendizábal, chairwoman of the
Supervisory Board thanked Dr. Starp and Mr. Gonzalo Rodriguez-Fraile Díaz
for their work and efforts for SYGNIS Pharma AG. She welcomed Dr. Franz
Wilhelm Hopp and Mr. Werner-Friedrich Knuth Schäfer as new members of the
Supervisory Board.
At the AGM Pilar de la Huerta, CEO/CFO, confirmed expectations that Qiagen
will launch first products with QualiPhi(R) by autumn 2013.
For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta(at)sygnis.es
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA
amplification and sequencing, and SYGNIS Pharma AG, listed in the German
Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03),
SYGNIS' new mission is to develop and distribute technologies and products
from X-Pol, which has a commercial product in the DNA amplification
segment, QualiPhi(R) and is currently developing other products in the
field of Next Generation Sequencing.
.
### Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions
of future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are
subject to known and unknown risks and imponderability and can be affected
by other factors as a consequence of which the actual results, plans and
goals of SYGNIS Pharma AG may deviate greatly from the established
conclusions or implied predictions contained in such statements. SYGNIS
does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason. ###
End of Corporate News
---------------------------------------------------------------------
30.08.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: 06221 454-6
Fax: 06221 454-700
E-mail: contact(at)sygnis.de
Internet: www.sygnis.de
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
228322 30.08.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.08.2013 - 10:58 Uhr
Sprache: Deutsch
News-ID 292408
Anzahl Zeichen: 6525
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 323 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: SYGNIS Pharma AG: Shareholders support Management proposals at"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS Pharma AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
